Magenta Therapeutics to Present at Investor Conferences in March
Cowen Healthcare Conferenceon March 11, 2019, at 2:10 p.m.at the Boston Marriott Copley Placein Boston, Mass. Oppenheimer Healthcare Conferenceon March 19, 2019, at 3:20 p.m.at the Westin New York Grand Centralin New York City.
Live webcasts of the presentations can be accessed under “Events & Presentations” in the Investors and Media section of the company’s website at www.magentatx.com. Replays of the webcasts will be archived on the Magenta website for 60 days following each presentation.
This press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “will,” “could”, “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “seeks,” “endeavor,” “potential,” “continue” or the negative of such words or other similar expressions can be used to identify forward-looking statements.
The express or implied forward-looking statements included in this press
release are only predictions and are subject to a number of risks,
uncertainties and assumptions, including, without limitation:
uncertainties inherent in clinical studies and in the availability and
timing of data from ongoing clinical studies; whether interim results
from a clinical trial will be predictive of the final results of the
trial; whether results from preclinical studies or earlier clinical
studies will be predictive of the results of future trials; the expected
timing of submissions for regulatory approval or review by governmental
authorities, including review under accelerated approval processes;
orphan drug designation eligibility; regulatory approvals to conduct
trials or to market products; whether Magenta's cash resources will be
sufficient to fund Magenta's foreseeable and unforeseeable operating
expenses and capital expenditure requirements; and other risks set forth
under the caption “Risk Factors” in Magenta’s Registration Statement on
Form S-1, as updated by Magenta’s most recent Quarterly Report on Form
10-Q and its other filings with the
Moreover, except as required by law, neither Magenta nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Manisha Pai, Vice President, Communications & Investor Relations